SPN-812
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Attention-Deficit/Hyperactivity Disorder (ADHD)
Conditions
Attention-Deficit/Hyperactivity Disorder (ADHD)
Trial Timeline
Jul 27, 2021 → Jul 26, 2023
NCT ID
NCT04786990About SPN-812
SPN-812 is a approved stage product being developed by Supernus Pharmaceuticals for Attention-Deficit/Hyperactivity Disorder (ADHD). The current trial status is completed. This product is registered under clinical trial identifier NCT04786990. Target conditions include Attention-Deficit/Hyperactivity Disorder (ADHD).
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06185985 | Approved | Completed |
| NCT04786990 | Approved | Completed |
| NCT04143217 | Phase 3 | Completed |
| NCT02736656 | Phase 3 | Active |
Competing Products
18 competing products in Attention-Deficit/Hyperactivity Disorder (ADHD)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| Atomoxetine | Eli Lilly | Approved | 85 |
| ABT-089 + atomoxetine + placebo | AbbVie | Phase 2 | 52 |
| ABT-089 + Placebo | AbbVie | Phase 2 | 52 |
| ABT-089 | AbbVie | Phase 2 | 52 |
| ABT-089 + placebo | AbbVie | Phase 2 | 52 |
| MK0249 + Concerta (methylphenidate) + Placebo | Merck | Phase 2 | 52 |
| Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR) + Placebo | Novartis | Approved | 85 |
| IR Viloxazine + Placebo | Supernus Pharmaceuticals | Phase 1/2 | 36 |
| SPN-812 | Supernus Pharmaceuticals | Approved | 80 |
| 100mg SPN-812 + Placebo | Supernus Pharmaceuticals | Approved | 80 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| Placebo + SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| Placebo + 100mg SPN-812 + 200mg SPN-812 + 300mg SPN-812 + 400mg SPN-812 | Supernus Pharmaceuticals | Phase 2 | 47 |
| SPN-812 | Supernus Pharmaceuticals | Phase 3 | 72 |
| TD-9855 + TD-9855 + Placebo | Theravance Biopharma | Phase 2 | 47 |